Ballard Spahr advised Pyramid Biosciences on the deal.Clinical-stage biotechnology company Pyramid Biosciences, Inc. announced the development of a global licensing deal for two cancer therapies worth up…
Pyramid Biosciences’ $864 Million Licensing Deal
